ORIGINAL ARTICLESLong-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychoticsTurner, Martina; Eerdekens, Elsb; Jacko, Maryc; Eerdekens, MariëllebAuthor Information aThe Larkfield Centre, Glasgow, UK bJohnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium cJohnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA Correspondence and requests for reprints to Mariëlle Eerdekens, Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, B-2340, Beerse, Belgium Tel: +11 32 14 60 62 74; fax: +11 32 14 60 50 89; e-mail: [email protected] Received 4 November 2003 Accepted 5 May 2004 International Clinical Psychopharmacology: July 2004 - Volume 19 - Issue 4 - p 241-249 doi: 10.1097/01.yic.0000133500.92025.20 Buy Metrics Abstract Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or zuclopenthixol decanoate for 4 months or longer. Each was considered symptomatically stable by investigators. After receiving two cycles of their conventional depot antipsychotic during the run-in period, patients were switched to receive long-acting risperidone every 2 weeks for 12 weeks at an initial dose of 25 mg. This dose could be increased in 12.5-mg increments at 4-week intervals. Ninety-two percent of the patients received all six injections; 62% received the 25-mg dose throughout the treatment period. Adverse events related to movement disorders were reported in 3%. Severity of movement disorders decreased during long-acting risperidone treatment. Positive and Negative Syndrome Scale (PANSS) total and factor scores and scores on the Clinical Global Impressions severity scale were significantly reduced during treatment; 48% of these stable patients showed further symptom improvement (≥20% decrease in PANSS score at endpoint). The results indicate that patients with schizophrenia who are symptomatically stable during treatment with a conventional depot antipsychotic can be safely and effectively switched to long-acting injectable risperidone without a prior transition to oral risperidone. © 2004 Lippincott Williams & Wilkins, Inc.